Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03326336 · ClinicalTrials.gov registry record · Phase 1
Dose-escalation Study to Evaluate the Safety and Tolerability of GS030 in Subjects With Retinitis Pigmentosa
A Phase 1 study of Non-syndromic Retinitis Pigmentosa, sponsored by GenSight Biologics.
- Active
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
- 3
- Study locations
NCT03326336 is a Phase 1 study of Non-syndromic Retinitis Pigmentosa that is active but no longer recruiting, run by GenSight Biologics. The registered enrollment target is 10 participants. The trial reports 3 study locations across 2 states.
The verdict
NCT03326336, a Phase 1 study of Non-syndromic Retinitis Pigmentosa, is active but no longer recruiting, sponsored by GenSight Biologics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
- 3
- Study locations
Study Summary
The objective of this study is to evaluate the safety and tolerability of escalating doses of a gene therapy called GS030-DP (injected study treatment) administered via a single intravitreal injection and repeated light stimulation using a medical device called GS030-MD (stimulating glasses) in subjects with documented diagnosis of non-syndromic Retinitis Pigmentosa
Conditions Studied
Interventions
- COMBINATION_PRODUCT Gene therapy: GS030-DP AND Medical device: GS030-MD
Study Locations (3)
Other
- Centre Hospitalier National d'Ophtalmologie (CHNP) des Quinze-Vingts - Paris
- Moorfields Eye Hospital NHS Foundation Trust, 162 City Road - London
Pennsylvania
- UPMC Eye Center - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2018-09-26 |
| Est. Completion | 2027-10-26 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03326336
The ClinicalTrials.gov registry entry for NCT03326336 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GenSight Biologics, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Non-syndromic Retinitis Pigmentosa appearing as the primary indexed condition, and to 1 intervention - of which Gene therapy: GS030-DP AND Medical device: GS030-MD is the first listed.
NCT03326336 reports 3 study locations spanning 2 distinct geographic areas - top geographies include Other, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT03326336 about?
NCT03326336 is a clinical study titled "Dose-escalation Study to Evaluate the Safety and Tolerability of GS030 in Subjects With Retinitis Pigmentosa". The objective of this study is to evaluate the safety and tolerability of escalating doses of a gene therapy called GS030-DP (injected study treatment) administered via a single intravitreal injection and repeated light stimulation using a medical device called GS030-MD (stimulating glasses) in subj...
What is the current status of trial NCT03326336?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2018-09-26. Estimated completion is 2027-10-26.
What conditions does trial NCT03326336 study?
This clinical trial studies the following conditions: Non-syndromic Retinitis Pigmentosa.
What interventions are being tested in trial NCT03326336?
The interventions under investigation include: Gene therapy: GS030-DP AND Medical device: GS030-MD (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT03326336?
This trial is sponsored by GenSight Biologics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03326336 being conducted?
This trial has 3 study locations across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.